Mr. Edwards brings to Biosion nearly 25 years of experience to Biosion in corporate strategy, Business Development, Alliance Management, M&A, corporate development and communications/investor relations. He began his career in research at the University of Colorado Health Sciences Center and has held pharma positions at Lexicon Pharmaceuticals, Valeant Pharmaceuticals, and most recently at Ionis Pharmaceuticals He has extensive knowledge of R&D, marketing approvals, commercial launch preparations and a track record of successful deal negotiations and partnerships.

During his career in the pharmaceutical industry, Joel managed collaborations that resulted in three NDA approvals while at Ionis (Genzyme/Kynamro, Biogen/Spinraza, and GSK/Tegsedi) and one NDA approval while at Valeant (GSK/Retigabine). The most successful partnership and marketed drug he managed has been Spinraza which currently generates over $2B in annual revenue. In total Joel was responsible for bringing in greater than $3.5B in business development and alliance revenue during time at Ionis and managed portfolio of more than 15 alliances that included multiple large pharma partners. Most recently at Ionis, Joel led the merger and integration of Ionis’ subsidiary, Akcea, resulting in $35M in savings in operating expenses. In addition, Joel was responsible for building Ionis’ commercialization capabilities and was leading a three-year company transformation project to prepare for the company’s first commercial launch.

Joel holds a MBA from Colorado State University and a BS in Psychology from Ball State University, graduating from both institutions with honors distinction.